- According to estimates from 9 analysts, Evommune, Inc. stock's average price target has fallen from $45.22 to $39.33, with forecasts ranging from $26 to $55 per share
- Based on the Jun. 26 closing price, the updated target implies approximately 56% potential upside
- Consensus rating remains at “Buy” across 11 covering analysts, with 10 Buys, 1 Holds and 0 Sells
Explore more price target data and ratings for Evommune, Inc. on the , and track all previous and future analyst recommendations for Evommune, Inc. in the dedicated .
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.